Literature DB >> 32343421

Thyroid Hormone Signaling and the Liver.

Megan J Ritter1, Izuki Amano1,2, Anthony N Hollenberg1.   

Abstract

Thyroid hormone (TH) plays a critical role in maintaining metabolic homeostasis throughout life. It is well known that the liver and thyroid are intimately linked, with TH playing important roles in de novo lipogenesis, beta-oxidation (fatty acid oxidation), cholesterol metabolism, and carbohydrate metabolism. Indeed, patients with hypothyroidism have abnormal lipid panels with higher levels of low-density lipoprotein levels, triglycerides (triacylglycerol; TAG), and apolipoprotein B levels. Even in euthyroid patients, lower serum-free thyroxine levels are associated with higher total cholesterol levels, LDL, and TAG levels. In addition to abnormal serum lipids, the risk of nonalcoholic fatty liver disease (NAFLD) increases with lower free thyroxine levels. As free thyroxine rises, the risk of NAFLD is reduced. This has led to numerous animal studies and clinical trials investigating TH analogs and TH receptor agonists as potential therapies for NAFLD and hyperlipidemia. Thus, TH plays an important role in maintaining hepatic homeostasis, and this continues to be an important area of study. A review of TH action and TH actions on the liver will be presented here.
© 2020 American Association for the Study of Liver Diseases.

Entities:  

Year:  2020        PMID: 32343421     DOI: 10.1002/hep.31296

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  22 in total

Review 1.  Targeting Thyroid Hormone/Thyroid Hormone Receptor Axis: An Attractive Therapy Strategy in Liver Diseases.

Authors:  Qianyu Tang; Min Zeng; Linxi Chen; Nian Fu
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

2.  Mediation effects of thyroid function in the associations between phthalate exposure and lipid metabolism in adults.

Authors:  Han-Bin Huang; Po-Keng Cheng; Chi-Ying Siao; Yuan-Ting C Lo; Wei-Chun Chou; Po-Chin Huang
Journal:  Environ Health       Date:  2022-07-01       Impact factor: 7.123

3.  Prevalence of Thyroid Dysfunction in a Chinese Population with Different Glucose Intolerance Status: A Community-Based Cross-Sectional Study.

Authors:  Xiuting Huang; Xiuying Zhang; Xianghai Zhou; Xueyao Han; Zuodi Fu; Yufeng Li; Linong Ji
Journal:  Diabetes Metab Syndr Obes       Date:  2020-11-16       Impact factor: 3.168

4.  Relationship Between Thyroid Hormone and Liver Steatosis Analysis Parameter in Obese Participants: A Case-Control Study.

Authors:  Shuqin Chen; Yong Jin; Miao Xu; Pingping Zhang; Ye Zhou; Xingjun Qian; Qifa Song; Shizhong Bu; Jing Sun; Li Li
Journal:  Diabetes Metab Syndr Obes       Date:  2022-03-22       Impact factor: 3.168

5.  Increased Hepatic Fat Content in Patients with Resistance to Thyroid Hormone Beta.

Authors:  Carolina Chaves; Eveline Bruinstroop; Samuel Refetoff; Paul M Yen; João Anselmo
Journal:  Thyroid       Date:  2021-02-19       Impact factor: 6.506

Review 6.  Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options.

Authors:  Daniela Maria Tanase; Evelina Maria Gosav; Ecaterina Neculae; Claudia Florida Costea; Manuela Ciocoiu; Loredana Liliana Hurjui; Claudia Cristina Tarniceriu; Mariana Floria
Journal:  Int J Mol Sci       Date:  2020-08-18       Impact factor: 5.923

Review 7.  Organogenesis in vitro.

Authors:  Kentaro Iwasawa; Takanori Takebe
Journal:  Curr Opin Cell Biol       Date:  2021-08-02       Impact factor: 8.382

8.  Neonatal thyroxine activation modifies epigenetic programming of the liver.

Authors:  Tatiana L Fonseca; Tzintzuni Garcia; Gustavo W Fernandes; T Murlidharan Nair; Antonio C Bianco
Journal:  Nat Commun       Date:  2021-07-21       Impact factor: 17.694

Review 9.  Dysregulated lipid metabolism links NAFLD to cardiovascular disease.

Authors:  Audrey Deprince; Joel T Haas; Bart Staels
Journal:  Mol Metab       Date:  2020-10-01       Impact factor: 8.568

Review 10.  Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.

Authors:  Kalliopi Pafili; Michael Roden
Journal:  Mol Metab       Date:  2020-11-19       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.